Search

Position of EHA on Clinical Trials

 

The challenge
In Europe, the number of clinical trials is steadily decreasing. From 2007 to 2010, their number has decreased by some 20 percent from 5,028 to 4,193.

Read more

Revision of the EU’s pharmaceutical legislation

Background on the reformIn April 2023, the European Commission (EC) published two proposals to revise the existing (and outdated) pharmaceutical legislation. This includes legislation on medicines for children and rare diseases.

Read more

Meeting Report: European School of Haematology International Conference of Haematological Disorders in the Elderly

The meeting started by reviewing demographic aspects, physiological changes encountered in the elderly, as well as the definition of older and elderly people, frailty and comorbidity.

Read more

Daratumumab Shows Remarkable Benefit in Relapsed or Refractory Multiple Myeloma in the POLLUX Study

Daratumumab is a fully human monoclonal antibody that binds to a novel target on myeloma cells.

Read more

Does the patient with myelofibrosis feel better through Pacritinib?

Pacritinib is an oral next-generation multikinase inhibitor with specificity for JAK2 and FLT3 being evaluated to treat myelofibrosis in two Phase 3 trials.

Read more

European Hematologists will discuss breakthroughs in blood disorders in Milan, Italy - June 12-15, 2014

About the EHA Annual Congress

Hematology is a specialty that covers everything to do with blood: its origin in the bone marrow, diseases of blood and their treatments.

Read more

Blood Disorders: European Hematologists gather in Stockholm, June 13-16, 2013

About the EHA Annual Congress

Hematology is a specialty that covers everything to do with blood: its origin in the bone marrow, diseases of blood and their treatments.

Read more